ReviewCancer treatment reviews2022
A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC).
Review in Cancer treatment reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 52 citations in OpenAlex.
- Observational
- Consistency of c-Met protein overexpression over time in patients with non-squamous non-small cell lung cancer.Histopathology · 2026Article
- Precision Medicine in Treating Lung Cancer: A Narrative Review on Treatments Targeting Oncogenic Genetic Mutations.Cureus · 2026Review
- The evolving role of neoadjuvant immunotherapy in resectable non-small cell lung cancer: a narrative review.Journal of thoracic disease · 2026Review
- The role of antibody-drug conjugates in the treatment of lung cancer.Frontiers in oncology · 2026Review
- Affibody-Derived Drug Conjugates Targeting The Epidermal Growth Factor Receptor Are Potent And Specific Cytotoxic Agents.ACS pharmacology & translational science · 2025Article
- Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions.Molecular cancer · 2025Review
- Efficacy and safety of antibody drug conjugate therapy in patients with human epidermal growth factor receptor 2-positive non-small cell lung cancer: A single-arm systematic review and meta-analysis.Oncology letters · 2025Article
- Exploring the therapeutic use and outcome of antibody-drug conjugates in ovarian cancer treatment.Oncogene · 2025Review
- Advances in molecular pathology and therapy of non-small cell lung cancer.Signal transduction and targeted therapy · 2025Review
- Current Biomarkers in Non-Small Cell Lung Cancer-The Molecular Pathologist's Perspective.Diagnostics (Basel, Switzerland) · 2025Review
- Recent advances of antibody-drug conjugates in treating breast cancer with different HER2 status.Therapeutic advances in medical oncology · 2025Review
- Mechanisms of resistance to antibody-drug conjugates in cancer therapy: molecular basis and therapeutic strategies.Cancer drug resistance (Alhambra, Calif.) · 2025Review
- Antibody-drug conjugate: a newly developed biological missile for tumor treatment.Frontiers in oncology · 2025Review
- Signal mining and analysis of adverse events of Brentuximab Vedotin base on FAERS and JADER databases.PloS one · 2025Article
- Therapeutic Potential of Datopotamab Deruxtecan in the Treatment of Advanced Non-Small Cell Lung Cancer: Evidence to Date.OncoTargets and therapy · 2025Review
- Review Deciphering the Potential of Nanotherapeutics in Lung Cancer Management.Current cancer drug targets · 2025Review
- Antibody-drug conjugate combinations in cancer treatment: clinical efficacy and clinical study perspectives.Frontiers in pharmacology · 2025Review
- Article
- [Research Progress and Perspectives of Antibody-drug Conjugates Targeting Trophoblast Cell Surface Antigen-2 in Advanced Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
Abstract
Even though both targeted and immunotherapy-based therapies have been established as frontline standard-of-care for patients with advanced lung cancer, adverse events, resistance, and disease progression remain unavoidable in most instances. In this scenario, chemotherapy is a popular salvage option, but it has restricted therapeutic index. Antibody-drug conjugates (ADCs) have emerged as a viable option. ADCs combine the specificity of monoclonal antibodies with the cytotoxic effects of chemotherapy to deliver cytotoxic payloads to cancer cells in a direct fashion. Among the promising ADCs used in advanced solid tumors, HER2 targeted ADCs of trastuzumab ematansine and trastuzumab deruxtecan are key drugs in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.